The Novocure QSD-QR-810 Optune Lua is a medical device designed for the treatment of recurrent glioblastoma multiforme (GBM). It uses Tumor Treating Fields (TTFields) to disrupt cancer cell division and slow tumor growth.
Specifications
- Product Name: Optune LuaTM for Non-Small Cell Lung Cancer
(NSCLC) - Indication: Concurrent with PD-1/PD-L1 inhibitors or docetaxel
for adult patients with metastatic non-small cell lung cancer who
have progressed on or after a platinum-based regimen. - Manufacturer: Not specified in the provided text.
FAQs
How does the Optune Lua work?
The Optune Lua delivers low-intensity, intermediate-frequency electric fields to the tumor site, which interferes with the cancer cells’ ability to divide. This targeted therapy aims to reduce tumor growth while minimizing damage to surrounding healthy tissue.
Who can use the Novocure QSD-QR-810 Optune Lua?
The Optune Lua is primarily for patients with recurrent glioblastoma multiforme (GBM) who have already undergone surgery and/or chemotherapy. A healthcare provider will determine if this device is appropriate based on the patient’s condition.
How long do patients need to use the Optune Lua QSD-QR-810 each day?
Patients are generally advised to use the Optune Lua for a minimum of 18 hours a day. Consistent use over time is crucial for optimal effectiveness in slowing tumor growth.
Are there any side effects associated with the Novocure Optune Lua?
Some common side effects include mild skin irritation at the site of electrode placement and fatigue. However, most side effects are manageable and should be discussed with a healthcare provider for proper care.
